Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT04230187 by Yanhong Deng, with a registry enrolment figure of 528 participants, started 2020-09-01 and due to reach its primary completion in 2026-09-01. Interventions recorded: mFOLFOXIRI plus Bevacizumab; mFOLFOX6 Plus Bevacizumab. Conditions listed: Colorectal Cancer. Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "\- Histological or cytological documentation of adenocarcinoma of the colon or rectum". Sites: China. No results are recorded here; the registry entry is the source.